Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights Reviva (NASDAQ: RVPH) reported full-year 2025 results and business updates on March 30, 2026. The company disclosed a net loss of $19.9M for 2025 and cash of $14.4M at year-end. Reviva received FDA written recommendations calling for a second Phase 3 trial and plans to initiate RECOVER-2 in mid-2026. The company completed NDA-enabling studies, cGMP registration manufacturing, and raised gross proceeds from public offerings in 2025–2026.

#RVPH Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/RVPH/reviva-reports...

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering Reviva Pharmaceuticals (NASDAQ: RVPH) priced a public offering to raise approximately $10.0 million by selling 6,666,667 common shares with attached Series G and Series H warrants at a combined price of $1.50 per share and warrant.The Series G and Series H warrants have an exercise price of $1.50; G warrants expire five years and H warrants expire 12 months from issuance. Closing is expected on or about March 20, 2026. The company intends to use proceeds to fund R&D, including the planned RECOVER-2 Phase 3 trial for brilaroxazine, and general corporate purposes.

#RVPH Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

www.stocktitan.net/news/RVPH/reviva-pharmac...

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and

#RVPH Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

www.stocktitan.net/news/RVPH/reviva-pharmac...

PRISM MORNING MOVERS
Premarket Gainers
Trinity Biotech plc ( #TRIB) up 83.28%
Highway Holdings Limited ( #HIHO) up 72.29%
PicoCELA Inc. ( #PCLA) up 63.28%
Syntec Optics Holdings, Inc. ( #OPTX) up 39.09%

Premarket Decliners
Reviva Pharma ( #RVPH) down -46%
Haxin Hildings ( #HXHX) down -43%

#RVPH: Brilaroxazine Poster Presentations buff.ly/rmqEQ6u

Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights Reviva Pharmaceuticals (NASDAQ: RVPH) reported Q3 2025 results and recent program milestones on November 13, 2025. Key clinical and corporate updates include a planned pre-NDA meeting with FDA in Q4 2025 and a targeted NDA submission in Q2 2026 for brilaroxazine in schizophrenia. The company reported positive 1-year open-label extension (OLE) data (N=446) showing sustained PANSS and functional improvements and generally favorable safety findings.Other highlights: European patent granted for brilaroxazine in pulmonary fibrosis, completed a public equity offering raising $9.0 million gross, reported a Q3 net loss of $4.0 million, and held $13.2 million cash as of September 30, 2025.

#RVPH Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/RVPH/reviva-reports...

#RVPH Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis

www.stocktitan.net/news/RVPH/reviva-announc...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#RVPH, #FLEX, #WU, #BANC, #VAL

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #RVPH 2.2x
2. #FLEX 2.2x
3. #WU 2.1x
4. #OXY 2.0x
5. #BANC 2.0x

#OptionFlow #OptionsTrading #Trading

PRISM Mid-Day Movers:
Critical Metals (NASDAQ: #CRML) +70% on $35M funding for Greenland project & U.S. stake interest.
Leap Therapeutics (NASDAQ: #LPTX) +64% after $58.9M crypto-backed funding & biotech boost.
Other movers: #HIVE +21%, #RVPH +16%, #SKYE -54%.
prismmarketview.com/prism-mid-da...

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and

#RVPH Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

www.stocktitan.net/news/RVPH/reviva-pharmac...

#RVPH: There May Be A Faster Way buff.ly/uN6suER

Reviva Narrows Loss 23% in Fiscal Q2 | The Motley Fool

#RVPH #9f8d14d8-3b4c-4457-9a24-7282f3c27d99 #data-news

Origin | Interest | Match

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights Reviva Pharmaceuticals (NASDAQ: RVPH) has reported significant progress in its brilaroxazine development program for schizophrenia treatment, alongside Q2 2025 financial results. The company successfully completed its Phase 3 RECOVER open-label extension (OLE) 1-year study, demonstrating sustained efficacy across all symptom domains and a well-tolerated safety profile.Key clinical achievements include robust broad-spectrum efficacy with improvements in PANSS total score (-18.1), positive symptoms (-5.0), and negative symptoms (-4.4). The company plans to meet with the FDA in Q4 2025 to discuss the path to approval, with a potential NDA submission targeted for Q2 2026.Financially, Reviva reported a net loss of $6.1 million ($0.12 per share) for Q2 2025, compared to $7.9 million in Q2 2024. The company's cash position stands at $10.4 million, bolstered by a recent $10.0 million public equity offering.

#RVPH Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/RVPH/reviva-reports...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks in new downtrend with Average Directional Index, Thu Jun 26th - #WCT #RVPH #LQDA #KLTR #AFYA #TEO #CAL - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Reviva Pharma Raises $10M: New Offering Includes Warrants with 5-Year Exercise Window at $0.50 Late-stage CNS therapeutics firm secures $10M through share offering with dual warrant structure. Proceeds to advance R&D pipeline. See complete terms.

#RVPH Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

www.stocktitan.net/news/RVPH/reviva-pharmac...

Late-Stage Pharma Reviva Announces Public Offering: Key Details on Stock and Warrant Sale Late-stage CNS drug developer Reviva plans stock and warrant offering to advance R&D pipeline. See offering terms and use of proceeds. Get Details

#RVPH Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

www.stocktitan.net/news/RVPH/reviva-pharmac...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks in new downtrend in Average Directional Index, Mon Jun 23rd - #TELO #PRFX #DTST #TALK #SJ #RVPH #PLRX #CERT #BTCT #ATOM #WGO #NL #MLNK #HBI #BCSF - More: crystalequityresearch.com/SmCpStr/ - #smallcap

#RVPH: Open Label Extension Results & Key Opinion Leader Discussion buff.ly/ruM78Zi

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia Reviva Pharmaceuticals (NASDAQ: RVPH) announced positive one-year data from its Phase 3 RECOVER open-label extension study of brilaroxazine for schizophrenia treatment. The study demonstrated sustained broad-spectrum efficacy across all symptom domains with a 35% discontinuation rate. The drug showed significant improvements in PANSS scores, with total score improvements of -10.7 at 6 months and -18.1 at 12 months. Safety data revealed only 8.5% of participants reported treatment-emergent adverse events, mostly mild (6.5%) or moderate (2.0%). Notable findings include minimal weight gain (1.52 kg), no drug-related serious adverse events, and improvements in multiple neuroinflammatory markers. The study's success supports brilaroxazine's potential as a novel treatment for schizophrenia, particularly addressing persistent negative symptoms and poor functional outcomes.

#RVPH Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

www.stocktitan.net/news/RVPH/reviva-announc...

#RVPH: 1Q:25 Results buff.ly/lLu90y6

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights Reviva Pharmaceuticals (NASDAQ: RVPH) reported Q1 2025 financial results and provided updates on its lead drug candidate brilaroxazine. The company completed its long-term open-label extension (OLE) trial with 446 participants, including 156 patients completing one year and 301 completing six months of treatment. The full dataset, including clinical response, safety, and biomarker data, is expected in Q2 2025. Reviva plans to initiate the Phase 3 RECOVER-2 trial in mid-2025 and targets an NDA submission in Q4 2026. Financially, Reviva reported a net loss of $6.4 million ($0.13 per share) for Q1 2025, compared to $7.4 million in Q1 2024. Cash position stood at $5.3 million as of March 31, 2025, down from $13.5 million at the end of 2024.

#RVPH Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/RVPH/reviva-reports...

#RVPH: M&A Deals Highlight Brilaroxazine Value buff.ly/6xqxwt5

Breakthrough: Reviva's Schizophrenia Treatment Delivers Powerful 1-Year Results, Losses Narrow Late-stage schizophrenia drug shows sustained efficacy with -20.8 point PANSS improvement. Net losses narrow to $29.9M as Phase 3 plans advance. Full analysis inside.

#RVPH Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

www.stocktitan.net/news/RVPH/reviva-reports...

Just In: ( NASDAQ: #RVPH ) Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#RVPH, #SOUN, #LUNR, #NFE, #TTD

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #RVPH 33% OTM
2. #SOUN 30% OTM
3. #BBAI 29% OTM
4. #LUNR 23% OTM
5. #RDDT 22% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#RVPH, #LUNR, #APP, #ZBRA, #PDD

#OptionFlow #OptionsTrading #Trading